Fast optoacoustic mesoscopy, using the skin as a window for therapeutic monitoring of local and systemic disease.

Informazioni relative al progetto

WINTHER

ID dell’accordo di sovvenzione: 871763

DOI

10.3030/871763

Progetto chiuso

Data della firma CE 5 Dicembre 2019

Data di avvio 1 Gennaio 2020

Data di completamento 31 Dicembre 2024

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Costo totale

€ 5 111 203,75

Contributo UE

€ 4 292 170,00

Coordinato da

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 4 - WINTHER (Fast optoacoustic mesoscopy, using the skin as a window for therapeutic monitoring of local and systemic disease.)

Periodo di rendicontazione: 2023-07-01 al 2024-12-31

Sintesi del contesto e degli obiettivi generali del progetto

Raster-scan optoacoustic mesoscopy (RSOM), which was developed under the EU Horizon 2020 project INNODERM, enables novel label-free, high-resolution optical imaging of previously invisible pathophysiological features at skin depths of 1-5 mm. The method has already shown great potential in diagnostic dermatology, and through preliminary testing it has become apparent that it can also assess progression and therapy of conditions not only in skin, but also in cardiovascular diseases and diabetes. However, the latter requires improvements in the speed of RSOM, which is where WINTHER begins.

The aim of WINTHER is to design and validate the next generation of RSOM, capable of operating at speeds up to two orders of magnitude faster. Such improvements will allow the new system, fast-RSOM (F-RSOM), to serve as a precision tool for therapy monitoring of inflammatory skin diseases and drive a paradigm shift in therapeutic monitoring of cardio-metabolic diseases.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the WINTHER project, both technical and scientific achievements have been made. Specifically, the:

(1) Design, manufacture and validation of a new class of single-element transducers. Partner Sonaxis has led the way in this task, developing and testing (with help from TUM and iThera) several new iterations of single-element transducers with the best-performing having been selected and integrated into the prototype.
(2) Design, characterization, and implementation of an optimal illumination scheme for improved illumination efficiency. Partners Sonaxis, TUM and iTHERA were involved in this effort, by simulating and testing several illumination schemes.
(3) Design, testing and finalization of the F-RSOM encapsulated handheld prototype and software (including quality control and the investigation of information processing systems and computational efficiency to bridge the gap between information generation and clinical outputs by partners Rayfos, iThera and TUM), ensuring that all design and operation protocols adhere to safety and regulatory standards.
(4) Development of algortihms and deep-learning pipelines by partner TUM for accurate feature extraction and identification of relevant biomarkers for treatment monitoring in diseases such as melonoma.
(5) Pre-clinical and clinical validation and testing in vivo of the F-RSOM for cardiometabolic and dermatologic disease therapy monitoring by partners HUNIMED and TUM.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The WINTHER F-RSOM prototype improves the capabilities of the previous RSOM device to include fast measurements for assessing and monitoring of skin inflammation and cardio-metabolic diseases. The far-reaching impact of WINTHER, then, is to provide a long-term comprehensive platform for monitoring and diagnosing disease and therapy progress in a portable, non-invasive, inexpensive, label-free, fast and safe way. The ambitions of the project are aligned with the documented unmet clinical need and international physician recommendations.
The major technological advances have been the development of state-of-the-art transducers, the design of a novel new ergonomic, portable scanner for non-invasive imaging and the construction of a new clinically-friendly software that enables high-quality optoacoustic imaging. In addition, new algorithms and deep learning methods have been implemented to identify new biomarkers from imaging feature extraction.
Going beyond current clinical designs on the market, the expected impact of the F-RSOM technology is to improve on cost, effectiveness and availability of therapeutic monitoring for dermatological and cardiovascular diseases, as well as diabetes. As such, the socio-economic impact of WINTHER could be substantial, as it can provide the first reliable set of parameters that facilitate proper diagnosis, monitoring and optimal treatment early on, which will benefit the healthcare system as a whole.

Winther Logo